Patents by Inventor Rosanna Kapeller-Libermann

Rosanna Kapeller-Libermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9175045
    Abstract: Biologically active crosslinked polypeptides with improved properties relative to their corresponding precursor polypeptides, having good cell penetration properties and reduced binding to human proteins; and methods of identifying and making such improved polypeptides.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: November 3, 2015
    Assignee: Aileron Therapeutics, Inc.
    Inventors: Huw M. Nash, David Allen Annis, Rosanna Kapeller-Libermann, Tomi K. Sawyer, Noriyuki Kawahata
  • Publication number: 20140323701
    Abstract: The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.
    Type: Application
    Filed: January 15, 2014
    Publication date: October 30, 2014
    Applicant: Aileron Therapeutics, Inc.
    Inventors: Huw M. Nash, Rosanna Kapeller-Libermann, Tomi K. Sawyer, Noriyuki Kawahata, Vincent Guerlavais, Matthew Iadanza
  • Publication number: 20140135255
    Abstract: The present invention provides biologically active crosslinked polypeptides with improved properties relative to their corresponding precursor polypeptides, having good cell penetration properties and reduced binding to human proteins. The invention additionally provides methods of identifying and making such improved polypeptides.
    Type: Application
    Filed: August 2, 2013
    Publication date: May 15, 2014
    Applicant: Aileron Therapeutics, Inc.
    Inventors: Huw M. Nash, David Allen Annis, Rosanna Kapeller-Libermann, Tomi K. Sawyer, Noriyuki Kawahata
  • Publication number: 20100291099
    Abstract: The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 20A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: June 17, 2010
    Publication date: November 18, 2010
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Maria A. Glucksmann, Mark J. Williamson, Fong-Ying Tsai, Laura A. Rudolph-Owen, Rosanna Kapeller-Libermann, Rachel E. Meyers, Lillian Wei-Ming Chiang, John Joseph Hunter
  • Patent number: 7776577
    Abstract: The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: August 17, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rosanna Kapeller-Libermann, John J. Hunter
  • Publication number: 20090269350
    Abstract: The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 20A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: December 16, 2008
    Publication date: October 29, 2009
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Maria A. Glucksmann, Mark J. Williamson, Fong-Ying Tsai, Laura A. Rudolph-Owen, Rosanna Kapeller-Libermann, Rachel E. Meyers, Lillian Wei-Ming Chiang, John Joseph Hunter
  • Patent number: 7482147
    Abstract: The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: December 21, 2005
    Date of Patent: January 27, 2009
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Maria A. Glucksmann, Mark J. Williamson, Fong-Ying Tsai, Laura A. Rudolph-Owen, Rosanna Kapeller-Libermann, Rachel E. Meyers, Lillian Wei-Ming Chiang, John J. Hunter
  • Publication number: 20060116508
    Abstract: The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: December 21, 2005
    Publication date: June 1, 2006
    Inventors: Maria Glucksmann, Mark Williamson, Fong-Ying Tsai, Laura Rudolph-Owen, Rosanna Kapeller-Libermann, Rachel Meyers, Lillian Chiang, John Hunter
  • Patent number: 7029895
    Abstract: The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC 17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: April 30, 2003
    Date of Patent: April 18, 2006
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Maria A. Glucksmann, Mark J. Williamson, Fong-Ying Tsai, Laura A. Rudolph-Owen, Rosanna Kapeller-Libermann, Rachel E. Meyers, Lillian Wei-Ming Chiang, John Joseph Hunter
  • Publication number: 20040009553
    Abstract: The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC 17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: April 30, 2003
    Publication date: January 15, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Maria A. Glucksmann, Mark J. Williamson, Fong-Ying Tsai, Laura A. Rudolph-Owen, Rosanna Kapeller-Libermann, Rachel E. Meyers, Lillian Wei-Ming Chiang, John Joseph Hunter
  • Publication number: 20030036074
    Abstract: The invention provides isolated nucleic acids molecules that encode novel polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a sequence of the invention has been introduced or disrupted. The invention still further provides isolated proteins, fusion proteins, antigenic peptides and antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: May 24, 2002
    Publication date: February 20, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Maria Alexandra Glucksmann, Rosanna Kapeller-Libermann